Genix Pharmaceuticals Corporation (GENPF)

Market Cap	897.45K -88.7%
Revenue (ttm)	49.00 -98.3%
Net Income	-64.14K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Average Volume	15,517
Open	0.0141
Previous Close	0.0300
Day's Range	0.0141 - 0.0141
52-Week Range	0.0138 - 0.0357
Beta	0.49
RSI	44.02
Earnings Date	Feb 26, 2026

About Genix Pharmaceuticals

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. It also markets and sells nutraceuticals and pharmaceutical products, su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: GENPF

Financial Performance

In fiscal year 2024, Genix Pharmaceuticals's revenue was 4,051, a decrease of -67.19% compared to the previous year's 12,347. Losses were -73,196, -98.33% less than in 2023.

Financial numbers in CAD